Major Investors Accumulate Danaher Shares Amid Price Weakness

Institutions are buying Danaher stock near its low. Focus is on the upcoming Q1 earnings report and the strategic $9.9B acquisition of Masimo to boost its diagnostics segment.

As Danaher's stock trades near its annual low, significant institutional buyers are taking advantage of the depressed valuation to build their stakes. Market attention is also turning toward the pending multi-billion dollar acquisition of Masimo, with the company's upcoming quarterly report in April set to provide further strategic clarity.

Upcoming Earnings and Strategic Acquisition in Focus

All eyes are on April 21, 2026, when Danaher is scheduled to release its first-quarter financial results. The company has a recent history of exceeding market expectations. For the fourth quarter of 2025, it reported adjusted earnings per share of $2.23, surpassing the consensus estimate of $2.14. Quarterly revenue saw a year-over-year increase of 4.6%, reaching $6.84 billion.

A central element of the firm's forward strategy is its planned $9.9 billion takeover of Masimo Corporation. Pending regulatory and shareholder approvals, the transaction is anticipated to close in the second half of 2026. Masimo is expected to be integrated as a standalone operating company within Danaher's diagnostics segment. This move is designed to substantially bolster the conglomerate's presence in acute care settings and broaden its technological portfolio.

Institutional Confidence Evident in Recent Purchases

Recent regulatory filings reveal a notable shift in sentiment among major investment firms. Toth Financial Advisory Corp boosted its position by more than 53% during the fourth quarter of 2025, raising its total holdings to 8,400 shares. Similarly, Aberdeen Group plc increased its stake by 12%, bringing its ownership to nearly 1.3 million shares. Market observers interpret these substantial purchases as a vote of confidence in the industrial conglomerate's long-term growth prospects, even as its share price seeks a floor following a period of weakness.

Analyst Outlook Remains Positive

Wall Street analysts maintain a generally optimistic stance. The consensus rating for Danaher stock stands at "Moderate Buy." With shares currently trading around $191, the average price target of $253.55 sits significantly above the present market value. The management's commentary on April 21 will be scrutinized for detailed insights into the operational performance and the strategic roadmap leading up to the integration of Masimo.